| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 01/20/2004 | US6680192 Method for producing polymers having a preselected activity |
| 01/20/2004 | US6680188 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof |
| 01/20/2004 | US6680175 Diagnosing cancer in humans; obtain biopsy of human tissue, detect and measure signal from bound polypeptide marker, evaluate humans for cancer |
| 01/20/2004 | US6680173 Diagnosis of tauopathies |
| 01/20/2004 | US6680171 Drug screening, genetic engineering |
| 01/20/2004 | US6680170 Polynucleotides encoding STE20-related protein kinases and methods of use |
| 01/20/2004 | US6680169 Poliovirus replicons encoding therapeutic agents and uses thereof |
| 01/20/2004 | US6680059 Vaccines containing ribavirin and methods of use thereof |
| 01/20/2004 | US6680058 Compositions and methods for contraception in or sterilization of mammals |
| 01/20/2004 | US6680057 Using protein comprising partial amino acid sequence 2 or 10 |
| 01/20/2004 | US6680056 Stimulating proliferation of cytolytic t cells |
| 01/20/2004 | US6680054 Macromolecular neuraminidase-binding compounds |
| 01/20/2004 | US6679859 Amelioration of ischemic damage using synthetic oxygen carriers |
| 01/20/2004 | CA2231632C Use of creatine analogues for the treatment of disorders of glucose metabolism |
| 01/20/2004 | CA2148599C Cdnas encoding human nmda-22a receptor subunit and isoforms of the human nmda-r1 receptor subunit, transfected cell line expressing them |
| 01/20/2004 | CA2090961C Specific binding agents |
| 01/20/2004 | CA2083027C Formation of protein microparticles by antisolvent precipitation |
| 01/15/2004 | WO2004005892A2 Antimicrobial activity of interferon-inducible elr chemokines |
| 01/15/2004 | WO2004005883A2 Secreted and cytoplasmic tumor endothelial markers |
| 01/15/2004 | WO2004005554A2 Antisense modulation of livin expression |
| 01/15/2004 | WO2004005552A1 Antisense modulation of tfg-beta 2 expression |
| 01/15/2004 | WO2004005551A1 Antisense modulation of nf-kappa-b p50 subunit expression |
| 01/15/2004 | WO2004005529A2 GEF-H1b: BIOMARKERS, COMPLEXES, ASSAYS AND THERAPEUTIC USES THEREOF |
| 01/15/2004 | WO2004005520A1 Method for preparing fusion polypeptide comprising epidermal growth factor and human serum albumin in plants |
| 01/15/2004 | WO2004005513A2 Methods for specifically inhibiting histone deacetylase-7 and 8 |
| 01/15/2004 | WO2004005512A1 Nove protein and use thereof |
| 01/15/2004 | WO2004005511A1 Tumor-lysing virus growing selectively in tumor cells |
| 01/15/2004 | WO2004005510A1 NOVEL Nogo RECEPTOR-LIKE POLYPEPTIDE AND DNA THEREOF |
| 01/15/2004 | WO2004005509A1 Method of examining allergic disaese and drug for treating the same |
| 01/15/2004 | WO2004005501A1 Regulation of human casein kinase i epsilon |
| 01/15/2004 | WO2004005494A1 Medium for culturing autologous human progenitor stem cells and applications thereof |
| 01/15/2004 | WO2004005489A2 Nucleic acids encoding sarcocystic neurona antigen and uses thereof |
| 01/15/2004 | WO2004005487A2 Polynucleotides encoding a novel testis-specific tubulin tyrosine-ligase-like protein, bgs42 |
| 01/15/2004 | WO2004005486A2 Mp21s as modifiers of the p21 pathway and methods of use |
| 01/15/2004 | WO2004005483A2 ADCY3S AS MODIFIERS OF THE p21 PATHWAY AND METHODS OF USE |
| 01/15/2004 | WO2004005476A2 Nucleic acid compositions for stimulating immune responses |
| 01/15/2004 | WO2004005473A2 Hcv fusion proteins with modified ns3 domains |
| 01/15/2004 | WO2004005467A2 Expression of human interferon in transgenic chloroplasts |
| 01/15/2004 | WO2004005461A2 Antisense modulation of insulin-like growth factor 2 expression |
| 01/15/2004 | WO2004005460A2 Antisense modulation of hmg-coa reductase expression |
| 01/15/2004 | WO2004005347A1 Thrombin-cleavable factor x analogues |
| 01/15/2004 | WO2004005346A2 Human nuclear hormone receptor |
| 01/15/2004 | WO2004005345A1 Inhibitors of the ephrin/ephb receptor interaction |
| 01/15/2004 | WO2004005342A1 Glp-1 and methods for treating diabetes |
| 01/15/2004 | WO2004005341A2 Full-length interferon gamma polypeptide variants |
| 01/15/2004 | WO2004005340A1 Fusion polypeptide comprising epidermal growth factor and human serum albumin |
| 01/15/2004 | WO2004005339A2 Cationic linear peptides having antibacterial and/or antifungal properties |
| 01/15/2004 | WO2004005338A1 Secreted peptides |
| 01/15/2004 | WO2004005337A1 Phosphoinositolglycan (pig)-binding protein from adipocytes |
| 01/15/2004 | WO2004005336A2 β-SHEET BREAKING PEPTIDES |
| 01/15/2004 | WO2004005331A2 Peptides derived from pep133 (g1p3, 6-16) |
| 01/15/2004 | WO2004005328A2 Peptidomimetic compound useful as inhibitor of integrins |
| 01/15/2004 | WO2004005327A1 Novel tubulysin analogues |
| 01/15/2004 | WO2004005326A2 Tubulysin conjugates |
| 01/15/2004 | WO2004005324A2 Peptide composition for treatment of sexual dysfunction |
| 01/15/2004 | WO2004005323A2 Affinity small molecules for the epo receptor |
| 01/15/2004 | WO2004005318A2 Peptides comprising aromatic d-amino acids and methods of use |
| 01/15/2004 | WO2004005316A2 Prevention and treatment of hcv infection employing antibodies directed against conformational and linear epitopes |
| 01/15/2004 | WO2004005312A1 Antisense modulation of ptprk expression |
| 01/15/2004 | WO2004005292A1 Novel antibiotics against vibrio anguillarum and the applications thereof in cultures of fish, crustaceans, molluscs and other aquaculture activities |
| 01/15/2004 | WO2004005286A2 Viral inhibitors |
| 01/15/2004 | WO2004005270A1 Aza-peptide epoxides |
| 01/15/2004 | WO2004005269A1 Method for producing substituted thiazol-2-yl methyl esters |
| 01/15/2004 | WO2004004833A1 Use of cyclooxygenase-2 selective inhibitors and thrombolytic agents for the treatment or prevention of a vaso-occlusive event |
| 01/15/2004 | WO2004004798A2 Central airway administration for systemic delivery of therapeutics |
| 01/15/2004 | WO2004004781A1 LIQUID FORMULATIONS WITH HIGH CONCENTRATION OF HUMAN GROWTH HORMONE (hgh) COMPRISING 1,2-PROLPYLENE GLYCOL |
| 01/15/2004 | WO2004004780A1 Liquid formulations with high concentration of human growth hormone (hgh) comprising phenol |
| 01/15/2004 | WO2004004779A1 Liquid formulations with a high concentration of human growth hormone (hgh) comprising glycine |
| 01/15/2004 | WO2004004774A2 Compositions comprising panthetine for the treatment of dyslipidemia |
| 01/15/2004 | WO2004004772A1 Remedy for diabetes |
| 01/15/2004 | WO2004004770A1 Chemotactic factor inhibitor for modulating inflammatory reactions |
| 01/15/2004 | WO2004004769A1 Conjugates of photosensitizers and oligonucleotides for selective photochemiotherapy |
| 01/15/2004 | WO2004004767A1 Treatment of autoimmune diseases |
| 01/15/2004 | WO2004004765A1 Treatment of autoimmune skin diseases |
| 01/15/2004 | WO2004004763A2 Use of hmgb1 in the treatment of tissue damage and/or to promote tissue repair |
| 01/15/2004 | WO2004004757A1 Treatment for eye disorder |
| 01/15/2004 | WO2004004756A1 Use of pthrp antagonists for treating renal cell carcinoma |
| 01/15/2004 | WO2004004755A1 Treatment of osteoporosis |
| 01/15/2004 | WO2004004754A1 Novel medicament combinations based on magnesium salts and fibrinolytics |
| 01/15/2004 | WO2004004753A1 Peptide having an immunoregulatory property and the composition of said peptide |
| 01/15/2004 | WO2004004750A2 Use of alanyl-aminopeptidase inhibitors and pharmaceutical compositions containing said inhibitors |
| 01/15/2004 | WO2004004749A1 Proteaseome inhibitors for the treatment of herpesviridae infected individuals |
| 01/15/2004 | WO2004004705A2 Pharmaceutical formulations for preparing drink products |
| 01/15/2004 | WO2004004698A2 Proteins binding to cross-beta structure comprising amyloid and methods for detection and modulation of the cross-beta structure, its formation and its associated toxicity |
| 01/15/2004 | WO2004004696A1 Controlled release composition |
| 01/15/2004 | WO2004004687A2 Liposomal vaccine |
| 01/15/2004 | WO2004004665A2 Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method |
| 01/15/2004 | WO2004004664A2 Methods for treating or preventing ischemic injury |
| 01/15/2004 | WO2004004663A2 Compositions and methods for ligament growth and repair |
| 01/15/2004 | WO2004004662A2 Compositions and methods for the diagnosis and treatment of tumor |
| 01/15/2004 | WO2004004661A2 Boroproline compound combination therapy |
| 01/15/2004 | WO2004004658A2 Methods and compositions relating to isoleucine boroproline compounds |
| 01/15/2004 | WO2004004656A2 Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs |
| 01/15/2004 | WO2004004653A2 Methods for treating psychosis associated with interferon-alpha therapy |
| 01/15/2004 | WO2004004649A2 Compositions and methods for the treatment of immune related diseases |
| 01/15/2004 | WO2004004643A2 Interferon gamma in the detection and treatment of angiomyolipomas |
| 01/15/2004 | WO2004004630A2 Osteoinductive biomaterials |
| 01/15/2004 | WO2004004551A2 Alpha-melanocyte stimulating hormone peptides protection in organ transplantation |
| 01/15/2004 | WO2004004482A1 Milk protein isolate and method for preparing same |
| 01/15/2004 | WO2003099868A3 Method for obtaining anti-idiotype antibodies |